New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
16:28 EDTCLVS, KING, PCG, BBRY, BIIB, RHOn The Fly: Closing Wrap
Stocks on Wall Street were higher, but closed well off their best levels, as the averages traded in a now-familiar pattern of a higher open followed by afternoon weakness. With just one trading day remaining in March, the Dow and S&P 500 are roughly flat for the month, while the Nasdaq has declined more than 3%. ECONOMIC EVENTS: In the U.S., personal income and consumer spending both rose 0.3% in February, matching expectations. The core PCE price index rose 0.1% in the month, which was also in-line with estimates. The final University of Michigan consumer sentiment reading for March came in at 80.0, which was down from February's 81.6 reading and a bit below expectations. In Europe, an index of executive and consumer sentiment rose to 102.4 in March from 101.2 in February, beating the consensus estimate of economists. COMPANY NEWS: BlackBerry (BBRY) reported a fourth quarter loss that was narrower than expected on revenue that missed expectations and fell below $1B for the first time since 2007. The handset maker said it sold 3.4M smartphones during the quarter. BlackBerry also said its cash and equivalents totaled $2.7B at March 1, down from $3.2B at the end of the prior quarter, and the company said it is targeting break-even cash flow by the end of its fiscal 2015. Shares of the company initially traded higher following the report, but closed down 64c, or 7.07%, to $8.41... King Digital (KING) lost another 41c, or 2.22%, to $18.08 to finish its first abbreviated week of trade down more than 14% following the "Candy Crush" maker's Wednesday initial public offering. MAJOR MOVERS: Among the notable gainers was home furnishing retailer Restoration Hardware (RH), up $8.12, or 12.73%, to $71.93 after its first quarter profit view beat estimates. Also higher were shares of Idera Pharmaceuticals (IDRA), up 69c, or 17.78%, to $4.57 after the company's Phase 2 trial of its treatment for moderate-to-severe plaque psoriasis met its primary objective. Among the noteworthy losers was PG&E Corporation (PCG), down $1.75, or 4.01%, to $41.89 after reporting that they expect that the federal government will bring criminal charges against the utility in connection with the 2010 San Bruno natural gas transmission pipeline accident. Following the announcement the stock was downgraded at Deutsche Bank and Citigroup. Also lower were a number of biotech names, including Clovis Oncology (CLVS), down $9.99, or 12.44%, to $70.33, and Biogen (BIIB), down $15.94, or 5.05%, to $294.12 as the sector continued to see significant weakness, as it often has in recent trade. INDEXES: The Dow was up 58.83, or 0.36%, to 16,323.06; the S&P 500 was up 8.58, or 0.46%, to 1,857.62; the Nasdaq was up 4.53, or 0.11%, to 4,155.76.
News For BBRY;KING;RH;PCG;CLVS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2015
06:50 EDTBIIBBiogen reports Q2 non-GAAP EPS $4.22, consensus $4.10
Subscribe for More Information
July 23, 2015
15:05 EDTBIIBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include AbbVie (ABBV), consensus $1.06... Biogen (BIIB), consensus $4.10... Simon Property Group (SPG), consensus $2.36... State Street (STT), consensus $1.37... V.F. Corp. (VFC), consensus 36c... Johnson Controls (JCI), consensus 91c... American Airlines (AAL), consensus $2.60... Rockwell Collins (COL), consensus $1.30... Cabot Oil & Gas (COG), consensus 4c... Lear (LEA), consensus $2.48... Encana (ECA), consensus (15c).
13:42 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
08:03 EDTBIIBBiogen update 'promising,' says RBC Capital
RBC Capital says that there were negative aspects to yesterday's update on the trial results of Biogen's Alzheimer's treatment. Specifically, the 6 mg version of the drug only slightly improved patients' performance on one cognition test compared with the most recently chosen group of ten patients taking placebos, and did not improve their performance at all on another cognition test. However, RBC says that the drug did improve patients' performance on both tests versus the 20+ patients who were in a previous placebo group. Additionally, the firm reports that the cognition test on which the patients taking the drug outperformed versus the newer placebo group is more widely accepted than the other cognition test. RBC sees a 50%-60% chance that the drug will succeed.
07:00 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 77, August is at 37, September is at 34; compared to its 52-week range of 23 to 46, suggesting large near term price movement into the expected release of Q2 results on July 24.
July 22, 2015
10:59 EDTBIIBBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:01 EDTBIIBOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:28 EDTBIIBBiogen downgraded to Neutral at Piper Jaffray after Alzheimer's data
Subscribe for More Information
09:22 EDTBIIBBiogen downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:07 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTBBRYBlackBerry agrees to acquire AtHoc, terms not disclosed
Subscribe for More Information
07:19 EDTBIIBBiogen drops 4.8% to $390 after reporting Alzheimer's drug data
06:50 EDTBIIBBiogen's Alzheimer's candidate shows reduction of clinical decline
Subscribe for More Information
July 21, 2015
17:50 EDTBBRYBlackBerry reports additional job cuts, CBC says
BlackBerry has disclosed an additional round of job cuts, the Canadian Broadcasting Corporation reported earlier, citing company statements. The company did not reveal how many employees were laid off, but noted that some were shifted to other positions within BlackBerry. Reference Link
06:24 EDTBIIBPiper expects 'stronger, bolder' move from Biogen
Subscribe for More Information
06:12 EDTBIIBBiogen implied volatility of 50 at upper end of index
July 20, 2015
10:00 EDTCLVSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:32 EDTBIIBAlzheimer's Association to hold a conference
Subscribe for More Information
06:52 EDTCLVSClovis upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
July 16, 2015
10:18 EDTKINGOptions with increasing implied volatility
Options with increasing implied volatility: SRPT ENR FOSL KING
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use